Skip to main content
Clinical Trials/NCT01769716
NCT01769716
Completed
Not Applicable

Umbilical Cord Blood Therapy for Children With Global Developmental Delay

MinYoung Kim, M.D.1 site in 1 country14 target enrollmentDecember 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Global Developmental Delay
Sponsor
MinYoung Kim, M.D.
Enrollment
14
Locations
1
Primary Endpoint
Changes in Cognition
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This open-label study aims to evaluate the safety and efficacy of autologous or allogeneic umbilical cord blood therapy for children with global developmental delay.

Detailed Description

Global developmental delay is defined as significant delay in two or more of the following developmental domains: gross/fine motor, speech/language, cognition, social/personal, and activities of daily living. Umbilical cord blood has been used for inherited metabolic diseases that feature global developmental delay and many experimental animal studies have revealed umbilical cord blood is useful to repair neurological impairments in brain.

Registry
clinicaltrials.gov
Start Date
December 2012
End Date
December 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
MinYoung Kim, M.D.
Responsible Party
Sponsor Investigator
Principal Investigator

MinYoung Kim, M.D.

Associate Professor

Bundang CHA Hospital

Eligibility Criteria

Inclusion Criteria

  • Global developmental delay
  • Willing to comply with all study procedure

Exclusion Criteria

  • Medical instability including pneumonia or renal function at enrollment
  • Poor cooperation of guardian,including inactive attitude for rehabilitation and visits for follow-up
  • Uncontrolled persistent epilepsy
  • Not eligible according to the principal investigator

Outcomes

Primary Outcomes

Changes in Cognition

Time Frame: Baseline - 6 months - 12 months

Korean Wechsler Preschool and Primary Scale of Intelligence (K-WPPSI) (Higher value means better cognitive function (K-WPPSI: below 70 - worst, over 130 - best)

Changes in Cognitive Neurodevelopmental Outcome

Time Frame: Baseline - 1 month - 3 months - 6 months - 12 months

Korean version of Bayley Scale of Infant Development-II Mental Scales (Higher value means better cognitive function: raw score 0 - worst, 178 - best.)

Secondary Outcomes

  • Changes in Standardized Gross Motor Function(Baseline - 1 month - 3 months - 6 months - 12 months)
  • Changes in Motor Performance(Baseline - 1 month - 3 months - 6 months - 12 months)
  • Changes in Functional Performance in Daily Activities(Baseline - 1 month - 3 months - 6 months - 12 months)
  • Changes in Motor Neurodevelopmental Outcome(Baseline - 1 month - 3 months - 6 months - 12 months)
  • Changes in Functional Independence in Daily Activities(Baseline - 1 month - 3 months - 6 months - 12 months)
  • Changes in Muscle Strength(Baseline - 1 month - 3 months - 6 months - 12 months)
  • Changes in Language Evaluation(Baseline - 6 months - 12 months)
  • Changes in Brain glucose metabolism(Baseline - 12 months)
  • Changes in Visual Perception Test(Baseline - 1 month - 3 months - 6 months - 12 months)

Study Sites (1)

Loading locations...

Similar Trials